Acute retroperitoneal hematoma following severe Covid-19 and the use of anticoagulants

INTRODUCTION: and Importance: Severe COVID19 patients under anticoagulant therapy are at the risk of developing hematoma. CASE PRESENTATION: We present case of 11 COVID19 who were presented with localized skin ecchymosis lesions in different areas of the body and retroperitoneal hematoma in the post...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzban-Rad, Saeid, Bahmani, Sahar, Kazemi, Amenehsadat, Taheri, Hamid Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173825/
https://www.ncbi.nlm.nih.gov/pubmed/35693103
http://dx.doi.org/10.1016/j.amsu.2022.103909
Descripción
Sumario:INTRODUCTION: and Importance: Severe COVID19 patients under anticoagulant therapy are at the risk of developing hematoma. CASE PRESENTATION: We present case of 11 COVID19 who were presented with localized skin ecchymosis lesions in different areas of the body and retroperitoneal hematoma in the posterior wall of the abdomen and chest. CLINICAL DISCUSSION: Cases of hematoma with severe COVID19 patients under anticoagulant therapy are reported in several case studies, particularly in geriatric population with the previous history of blood and/or cardiac disorders. CONCLUSION: These patients should be carefully monitored for hematomas by skilled nurse and practitioner and timely treated and monitored. -

Ejemplares similares